Psychiatry and Neurology, Neurology · Beaumont, TX
NPI
1790892396
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2929 Calder St, Suite 100
Beaumont, TX, 77702
Phone (409) 833-9797
Groups this clinician bills Medicare through
Medicare paid, 2024
$46K
593 services
Medicare patients, 2024
318
Average age 70
Drug cost, 2024
$5.7M
9,450 prescriptions
Company payments, 2025
$3,205
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Julius F Deiparine was code 99214 (office e&m - established), 395 times for 248 patients. In total Julius F Deiparine billed 593 services in 15 codes, and Medicare paid $46K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 395 | 248 | $77.08 | $30K |
| 99204 Office E&M - New | Office | 81 | 81 | $114.24 | $9,254 |
| 95886 Electrical Nerve Conductivity | Office | 42 | 21 | $69.83 | $2,933 |
| 99213 Office E&M - Established | Office | 30 | 29 | $40.53 | $1,216 |
| 95910 Electrical Nerve Conductivity | Office | 13 | 13 | $118.65 | $1,542 |
By year: 2022 $61K for 836 services; 2023 $49K for 744 services; 2024 $46K for 593 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 19 | 18 | $8.40 | $160 |
| 85025 Blood Count | 15 | 15 | $7.61 | $114 |
| 83880 Clinical Chemistry | 14 | 14 | $38.47 | $539 |
| 80053 Clinical Chemistry | 14 | 14 | $10.35 | $145 |
| 85652 Clinical Chemistry | 14 | 14 | $2.65 | $37.1 |
| 82550 Clinical Chemistry | 13 | 13 | $6.38 | $82.94 |
| 86140 Clinical Chemistry | 12 | 12 | $5.08 | $60.96 |
Medicare prescription drug claims, 2024
In 2024, the drug Julius F Deiparine prescribed most often to Medicare patients was Nortriptyline Hcl, with 801 prescriptions and refills. In total Julius F Deiparine wrote 9,450 Medicare prescriptions that cost $5.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Nortriptyline Hcl Generic | 801 | 1,530 | 218 | $16K |
| Zonisamide Generic | 781 | 1,665 | 219 | $25K |
| Levetiracetam Generic | 436 | 878 | 103 | $17K |
| Nuplazid Pimavanserin Tartrate | 408 | 443 | 75 | $2.1M |
| Clopidogrel Clopidogrel Bisulfate | 381 | 1,024 | 124 | $3,287 |
| Rivastigmine Generic | 372 | 913 | 142 | $67K |
| Gabapentin Generic | 359 | 763 | 100 | $7,657 |
| Donepezil Hcl Generic | 349 | 801 | 97 | $4,924 |
| Atorvastatin Calcium Generic | 300 | 815 | 100 | $3,198 |
| Topiramate Generic | 265 | 602 | 64 | $5,026 |
| Memantine Hcl Generic | 264 | 616 | 72 | $6,870 |
| Quetiapine Fumarate Generic | 260 | 607 | 77 | $4,492 |
| Oxcarbazepine Generic | 230 | 490 | 68 | $13K |
| Duloxetine Hcl Generic | 226 | 618 | 80 | $6,007 |
| Primidone Generic | 219 | 571 | 59 | $4,936 |
Brand drugs: 1,595 claims; generic drugs: 7,824 claims; opioid claims: 118.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Julius F Deiparine $3,205 ($3,205 in general payments such as food, travel and fees) from 20 companies. The largest payer was Neurelis, Inc. with $814.
| Company | Payments | Amount |
|---|---|---|
| Neurelis, Inc. | 23 | $814 |
| Abbvie Inc. ABBV | 48 | $648 |
| ACADIA Pharmaceuticals Inc ACAD | 34 | $454 |
| Lundbeck LLC | 27 | $415 |
| Teva Pharmaceuticals USA, Inc. TEVA | 8 | $147 |
| SK Life Science, Inc. | 13 | $142 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 8 | $136 |
| Neurocrine BioSciences, Inc. NBIX | 4 | $104 |
| Mallinckrodt Hospital Products Inc. | 5 | $84.95 |
| Amneal Pharmaceuticals LLC AMRX | 2 | $46.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.